Stem Cells Taken From Teeth Can Make Brain-like Cells

May 1, 2014

Image Caption: This is the distinct neuronal-like appearance of a mouse-derived dental pulp stem cell following the induction process. Credit: Dr. Kylie Ellis, University of Adelaide.

University of Adelaide

University of Adelaide researchers have discovered that stem cells taken from teeth can grow to resemble brain cells, suggesting they could one day be used in the brain as a therapy for stroke.

In the Universitys Centre for Stem Cell Research, laboratory studies have shown that stem cells from teeth can develop and form complex networks of brain-like cells. Although these cells havent developed into fully fledged neurons, researchers believe its just a matter of time and the right conditions for it to happen.

Stem cells from teeth have great potential to grow into new brain or nerve cells, and this could potentially assist with treatments of brain disorders, such as stroke, says Dr Kylie Ellis, Commercial Development Manager with the Universitys commercial arm, Adelaide Research & Innovation (ARI).

Dr Ellis conducted this research as part of her Physiology PhD studies at the University, before making the step into commercialization. The results of her work have been published in the journal Stem Cell Research & Therapy.

The reality is, treatment options available to the thousands of stroke patients every year are limited, Dr Ellis says. The primary drug treatment available must be administered within hours of a stroke and many people dont have access within that timeframe, because they often cant seek help for some time after the attack.

Ultimately, we want to be able to use a patients own stem cells for tailor-made brain therapy that doesnt have the host rejection issues commonly associated with cell-based therapies. Another advantage is that dental pulp stem cell therapy may provide a treatment option available months or even years after the stroke has occurred, she says.

Dr Ellis and her colleagues, Professors Simon Koblar, David OCarroll and Stan Gronthos, have been working on a laboratory-based model for actual treatment in humans. As part of this research Dr Ellis found that stem cells derived from teeth developed into cells that closely resembled neurons.

See the rest here:
Stem Cells Taken From Teeth Can Make Brain-like Cells

Novartis abandons plans to buy Gamida Cell

Elbit Medical Technologies Ltd. (TASE:EMTC) and Clal Biotechnology Industries Ltd. (TASE: CBI) announced this morning that talks to sell stem cell cancer treatment developer Gamida Cell have broken down. Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ) had been in talks to acquire Gamida Cell for $200-300 million cash with the potential for a further three hundred million dollars in milestone payments and royalties. Sources inform "Globes" that Novartis decided not to approve the deal.

It is not clear what is Novartis's reason for pulling out of the deal. Novartis had never publicly acknowledged that there were talks in the first place, although they had signed a memorandum of understanding including the exact financial conditions of the deal.It is unusual for a deal to reach such an advanced stage and not be realized, even though this was a very advanced deal and it was related to future strategic directions.

The main casualties of the decision were Gamida Cell's shareholders - Elbit Medical (30%) and Clal Biotechnology (22%).

Gamida Cell has proprietary technology for growing the number and density of stem cells within a specific blood sample. This capability could be a basis for all stem cell activity. The company seeks to enhance umbilical cord blood donations for implants to cure blood cancer in adults. Currently, umbilical cord blood can only be used for implant in people weighing less than 45 kilograms.

Gamida-Cell's first product was jointly developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) but the US Food and Drug Administration (FDA) retroactively tightened clinical trial requirements rendering the product's development uneconomical. The company is developing what it says is an improved product in the same field. The product is undergoing clinical trials, and because of its expected improved efficacy, justifies the high development cost.

Gamida-Cell is also considering an IPO on Wall Street.

Published by Globes [online], Israel business news - http://www.globes-online.com - on May 1, 2014

See the rest here:
Novartis abandons plans to buy Gamida Cell

Stem cell breakthrough in treating heart attacks

An implanted graft of cardiac cells derived from human stem cells (green) meshed with a monkey's own heart cells (red). Picture: Murry Lab/University of Washington/PA

Stem cell heart repair treatments could be tested on human patients within four years following a ground-breaking study of monkeys.

Scientists successfully restored damaged cardiac muscle in macaque monkeys suffering the after-effects of experimentally induced heart attacks, paving the way to clinical trials.

Researchers injected 1bn immature heart muscle cells derived from human embryonic stem cells into each animals heart.

Over several weeks, the new cells developed, assembled into muscle fibres, and began to beat in correct time. On average, 40% of the damaged heart tissue was regenerated.

It is the first time stem cell therapy for damage caused by heart attacks has been shown to work in a primate.

Lead scientist Prof Charles Murry, director of the Centre for Cardiovascular Biology at the University of Washington in Seattle, said: Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularise damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart.

He expects the treatment to be ready for clinical trials in human patients within four years.

Heart attack symptoms were triggered in the monkeys by blocking the coronary artery the main artery supplying the heart with blood for 90 minutes.

In humans, the reduced blood flow caused by narrowing of the arteries has a similar effect. Lack of blood flow to the heart damages the heart muscle by depriving it of oxygen.

Read more here:
Stem cell breakthrough in treating heart attacks

Stem cells from teeth can make brain-like cells

University of Adelaide researchers have discovered that stem cells taken from teeth can grow to resemble brain cells, suggesting they could one day be used in the brain as a therapy for stroke.

In the University's Centre for Stem Cell Research, laboratory studies have shown that stem cells from teeth can develop and form complex networks of brain-like cells. Although these cells haven't developed into fully fledged neurons, researchers believe it's just a matter of time and the right conditions for it to happen.

"Stem cells from teeth have great potential to grow into new brain or nerve cells, and this could potentially assist with treatments of brain disorders, such as stroke," says Dr Kylie Ellis, Commercial Development Manager with the University's commercial arm, Adelaide Research & Innovation (ARI).

Dr Ellis conducted this research as part of her Physiology PhD studies at the University, before making the step into commercialisation. The results of her work have been published in the journal Stem Cell Research & Therapy.

"The reality is, treatment options available to the thousands of stroke patients every year are limited," Dr Ellis says. "The primary drug treatment available must be administered within hours of a stroke and many people don't have access within that timeframe, because they often can't seek help for some time after the attack.

"Ultimately, we want to be able to use a patient's own stem cells for tailor-made brain therapy that doesn't have the host rejection issues commonly associated with cell-based therapies. Another advantage is that dental pulp stem cell therapy may provide a treatment option available months or even years after the stroke has occurred," she says.

Dr Ellis and her colleagues, Professors Simon Koblar, David O'Carroll and Stan Gronthos, have been working on a laboratory-based model for actual treatment in humans. As part of this research Dr Ellis found that stem cells derived from teeth developed into cells that closely resembled neurons.

"We can do this by providing an environment for the cells that is as close to a normal brain environment as possible, so that instead of becoming cells for teeth they become brain cells," Dr Ellis says.

"What we developed wasn't identical to normal neurons, but the new cells shared very similar properties to neurons. They also formed complex networks and communicated through simple electrical activity, like you might see between cells in the developing brain."

This work with dental pulp stem cells opens up the potential for modelling many more common brain disorders in the laboratory, which could help in developing new treatments and techniques for patients.

Follow this link:
Stem cells from teeth can make brain-like cells

Stem Cell Treatment In Panama Working Wonders – Video

Stem Cell Treatment In Panama Working Wonders
This is an update on Beverly after only 10 days in Panama for Stem Cell Treatment. She is feeling so much better and you can see it just by the look on her face. She has Secondary Progressive...

By: Stem Cell Patient

Original post:
Stem Cell Treatment In Panama Working Wonders - Video

Regenexx – Stem Cell Therapy for Arthritis and Injuries …

Welcome to Regenexx Stem Cell Procedures for Arthritis & Injuries Chris Centeno 2009-09-30T12:05:38+00:00 The Regenexx Procedures are a family of non-surgical stem cell and blood platelet treatments for common injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patients own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone. Regenexx Stem Cell and Blood Platelet Procedures offer a viable alternative for individuals suffering from joint pain, or who may be considering elective surgery or joint replacement due to injury or arthritis. Patients avoid the lengthy periods of downtime, and painful rehabilitation that typically follow invasive surgeries. Commonly Treated Conditions - Regenexx Stem Cell and Platelet Procedures

The list below represents the most commonly treated conditions using Regenexx stem cell or platelet procedures. It is not a complete list, so please contact us or complete the Regenexx Candidate Form if you have questions about whether you or your condition can be treated with these non-surgical procedures. The type of procedure used (stem cell or blood platelet) to treat these conditions is largely dependent upon the severity of the injury or condition.

The Centeno-Schultz Clinic is theoriginalstem cell based musculoskeletal practice in the U.S., with more stem cell orthopedics experience than any other clinic. We are also physician leaders in stem cell treatments for arthritis and injuries in terms of research presentations, publications, and academic achievements.

The episode features Dr. Centeno and Dr. Hanson, along with patient Barbee James, who required stem cell treatment after a failed micro fracture and continued problems following traditional knee surgery. The episode provided a nice overview of a Regenexx-SD (same-day) stem cell procedure for Barbees knee cartilage damage.

On February 28, 2013 Seattle King TV featured Regenexx patient Paul Lyon, who underwent a Regenexx-SD knee procedure in our Broomfield clinic. The story looks at his results and includes an interview with Dr. Christopher Centeno, along with footage in our advanced lab where stem cells are processed as part of the procedure.

Regenexx Network Physician Dr. Mayo Friedlis (Washington D.C. area) is featured in this recent news story about stem cell therapy, which explores the Regenexx-SD stem cell procedure and a very active seniors outcome following his knee stem cell injection.

Our Pittsburgh, PA. Regenexx Network Provider, Rehabilitation and Pain Specialists, was recently featured in a news story about treating a patients knee pain with stem cells. The patient returned to their clinic for this procedure after experiencing success with the stem cell treatment he received on his other knee.

See original here:
Regenexx - Stem Cell Therapy for Arthritis and Injuries ...

Stem cell cloning may be aid treatment for diabetes

Scientists have moved one step closer to creating and effective diabetes treatment by creating insulin-producing cells with the DNA of a diabetic woman.

The approach could someday aid treatment of the Type 1 form of the illness, which is usually diagnosed in childhood and accounts for about 5 percent of diabetes cases in the U.S. The disease kills insulin-making cells in the pancreas. People with Type 1 diabetes use shots or a small pump to supply the hormone, which is needed to control blood sugar.

The new work is a step toward providing genetically matched replacement cells for transplant, said Dieter Egli of the New York Stem Cell Foundation Research Institute in New York. He led the research, which was reported online Monday in the journal Nature.

Doug Melton of the Harvard Stem Cell Institute, who was not involved with the work, called the paper an impressive technical achievement. But he said he believed the cells would be useful as a research tool rather than a source of transplants. They could help scientists uncover what triggers Type 1 diabetes, he said, which could in turn lead to better therapies.

Scientists had previously made insulin cells that match diabetic patients by another means, so the new work gives researchers another option for comparison. Researchers are also exploring transplants of insulin-producing cells from cadavers as a potential treatment.

The latest work used a technique that partially resembles the process used to clone animals. Basically, scientists put DNA from the woman's skin cells into donated human eggs. The eggs were grown into early embryos. From these, the scientists removed stem cells, which can grow into any cell type in the body. These stem cells were turned into the insulin-producing cells.

Egli told reporters that these cells have shown promise in animal tests, but that he could not estimate a timetable for human experiments. The new work is the third report of using the cloning approach to make human stem cells, and the first using the technique to create insulin-making cells.

Stem cells cloning is an area of research that's showing promise to treat a number of diseases. In January, Dr. Jon LaPook, chief medical correspondent for CBS News, reported an experimental stem cell treatment for patients with multiple sclerosis. Scientists have also been able to repair bones using the stem cells of fatty tissue and also use cloned cells can repair a damaged heart.

Continue reading here:
Stem cell cloning may be aid treatment for diabetes

Stem Cell Therapies Look Promising For Heart Disease

Stem cell therapies work as a complement to standard treatments, potentially cutting the number of deaths after a year, suggests evidence from the latest Cochrane review: Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Taking stem cells from a patients bone marrow and injecting them into their damaged heart may be an effective way to treat heart disease.

The new review, published in The Cochrane Library, uses data involving 1,255 people from 23 randomised controlled trials, where all participants received standard treatments. Compared to standard treatment alone or with placebo, stem cell therapy using bone marrow cells resulted in fewer deaths due to heart disease and heart failure, reduced the likelihood of patients being readmitted to hospital, and improved heart function. However, researchers say that with much larger clinical trials underway, the findings are awaited to enable more certainty about the effects.

Dr Enca Martin-Rendon, author of the review, Cochrane Heart Review Group, and based at NHS Blood and Transplant and the University of Oxford, UK, said: This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, it is generated from small studies and it is difficult to come to any concrete conclusions until larger clinical trials that look at longer- term effects are carried out.

Stem cell therapies are experimental treatments that are currently only available in facilities carrying out medical research. If eventually found to be effective, they might offer an alternative or complementary treatment to standard drug and surgical treatments for some patients with chronic heart disease. The procedure involves collecting stem cells from a patient's own blood or bone marrow and using them to repair damaged tissues in the patient's heart and arteries.

Although within the first year there were no clear benefits of stem cell therapy over standard treatment alone, when longer term data were analysed a year or more later about 3 per cent of people treated with their stem cells had died compared with 15 per cent of people in the control groups. Hospital readmissions were reduced to 2 in every 100 people compared to 9 in the control group, and adverse effects were rare.

Dr Martin-Rendon continued, It isn't clear which types of stem cells work best or why stem cell therapies seem to work for some people but not for others. We need to find out what's different in the people who aren't responding well to these treatments as it might then be possible to tailor therapies to these patients, so that they work better."

Dr David Tovey, Editor-in-Chief, Cochrane, said: This review should help to raise awareness of the potential of stem cell therapy to improve patient outcomes, but it also demonstrates the importance of recognising the uncertainty of initial findings and the need for further research. A Cochrane review aims to analyse all available data to give a clear picture of what the evidence shows. Ensuring health decision makers, health professionals and the general public has access to up-to-date, relevant evidence research will help to raise awareness of the effectiveness of treatments and medications and therefore improve health care.

Cochrane Library

Visit link:
Stem Cell Therapies Look Promising For Heart Disease

Study of stem cell trials links discrepancies in data with reported success of treatment

PUBLIC RELEASE DATE:

28-Apr-2014

Contact: Franca Davenport f.davenport@imperial.ac.uk 020-759-42198 Imperial College London

New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data.

Researchers from Imperial College London conducted a meta-analysis of 49 randomised controlled trials of bone marrow stem cell therapy for heart disease. The study, published today in the British Medical Journal, identified and listed over 600 discrepancies within the trial reports.

Discrepancies were defined as two (or more) reported facts that could not both be accurate because they were logically or mathematically incompatible. For example, one trial reported that it involved 70 patients, who were divided into two groups of 35 and 80.

The researchers found eight trials that each contained over 20 discrepancies.

The researchers found that the discrepancy count in a trial was the most important determinant of the improvement in cardiac function reported by that trial. Trials with fewer and fewer discrepancies showed progressively smaller improvements in cardiac function. The five trials with no discrepancies at all showed an effect size of zero (see bar chart in Notes to Editors).

Previous meta-analyses looking at the results of lots of clinical trials have suggested that on average, bone marrow stem cell therapy has a significant positive effect on improving heart function. However, some trials have shown that it successfully improves heart function whilst others have not. The reasons for this are unclear.

Professor Darrel Francis, one of the study authors from the National Heart and Lung Institute at Imperial College London, said: "Clinical trials involve a huge amount of data and so it is understandable that discrepancies sometimes arise when researchers are presenting their findings. However, our study suggests that these discrepancies can have a significant impact on the overall results. It is a powerful reminder to all of us conducting clinical trials to be careful and vigilant to avoid discrepancies appearing in the work.

Read more:
Study of stem cell trials links discrepancies in data with reported success of treatment

Stem Cell Institute Welcomes Special Guest Speaker Roberta F. Shapiro DO, FAAPM&R to Stem Cell Therapy Public Seminar …

New York, NY (PRWEB) April 29, 2014

The Stem Cell Institute located in Panama City, Panama, welcomes special guest speaker Roberta F. Shapiro, DO, FAAPM&R to its public seminar on umbilical cord stem cell therapy on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Dr. Shapiro will discuss A New York Doctors Path to Panama.

Dr. Shapiro operates a private practice for physical medicine and rehabilitation in New York City. Her primary professional activities include outpatient practice focused on comprehensive treatment of acute and chronic musculoskeletal and myofascial pain syndromes using manipulation techniques, trigger point injections, tendon injections, bursae injections, nerve and motor point blocks. Secondary work at her practice focuses on the management of pediatric onset disability.

She is the founder and president of the Dayniah Fund, a non-profit charitable foundation formed to support persons with progressive debilitating diseases who are faced with catastrophic events such as surgery or illness. The Dayniah Fund educates the public about the challenges of people with disabilities and supports research on reducing the pain and suffering caused by disabling diseases and conditions.

Dr. Shapiro serves as assistant clinical professor in the Department of Rehabilitation and Regenerative Medicine at Columbia University Medical Center.

Stem Cell Institute Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Continue reading here:
Stem Cell Institute Welcomes Special Guest Speaker Roberta F. Shapiro DO, FAAPM&R to Stem Cell Therapy Public Seminar ...